Recursion Pharmaceuticals Inc Cl A (RXRX)

Feb 18, 2025, 11:00 AM EST - 4 days ago

Altitude Lab Startups Raise $154M in Capital

Feb 13, 2025, 6:05 PM EST - 9 days ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 5, 2025, 5:24 PM EST - 17 days ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Jan 7, 2025, 9:15 AM EST - 6 weeks ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 6, 2025, 8:30 AM EST - 6 weeks ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Dec 20, 2024, 4:05 PM EST - 2 months ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 12, 2024, 6:07 AM EST - 2 months ago

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Dec 9, 2024, 6:00 PM EST - 2 months ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Dec 9, 2024, 3:14 PM EST - 2 months ago

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Nov 20, 2024, 7:00 AM EST - 3 months ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 13, 2024, 9:08 AM EST - 3 months ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 12, 2024, 4:54 PM EST - 3 months ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Oct 30, 2024, 8:22 AM EDT - 4 months ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Oct 22, 2024, 8:00 AM EDT - 4 months ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Oct 6, 2024, 2:00 PM EDT - 4 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EDIT EXAS

Oct 2, 2024, 8:32 AM EDT - 5 months ago

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

Oct 2, 2024, 8:00 AM EDT - 5 months ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Sep 4, 2024, 1:03 PM EDT - 6 months ago

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 3, 2024, 8:11 AM EDT - 6 months ago

Recursion's blood vessel disorder drug meets main goal in mid-stage study

Aug 9, 2024, 9:00 AM EDT - 7 months ago

Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner

EXAI

Aug 9, 2024, 8:25 AM EDT - 7 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 5:37 PM EDT - 7 months ago

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

EXAI

Aug 8, 2024, 2:41 PM EDT - 7 months ago

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 7:39 AM EDT - 7 months ago

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Aug 8, 2024, 7:08 AM EDT - 7 months ago

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

EXAI

Aug 8, 2024, 1:32 AM EDT - 7 months ago

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Aug 5, 2024, 4:01 PM EDT - 7 months ago

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

Aug 1, 2024, 6:35 PM EDT - 7 months ago

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Jun 26, 2024, 10:07 PM EDT - 8 months ago

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Jun 26, 2024, 4:06 PM EDT - 8 months ago

Recursion Announces Proposed Offering of Class A Common Stock

Jun 24, 2024, 6:18 PM EDT - 8 months ago

Recursion CEO Chris Gibson talks integrating AI into drug development process

Jun 24, 2024, 9:00 AM EDT - 8 months ago

Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data

Jun 24, 2024, 8:00 AM EDT - 8 months ago

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

Jun 24, 2024, 3:36 AM EDT - 8 months ago

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Jun 17, 2024, 10:53 AM EDT - 8 months ago

Recursion Pharmaceuticals: Unprecedented Scale

Jun 8, 2024, 11:37 AM EDT - 9 months ago

Nvidia Owns These 4 Stocks. Here's How They're Doing.

NVDA ARM NNOX SOUN

May 29, 2024, 3:27 PM EDT - 9 months ago

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

May 24, 2024, 4:30 PM EDT - 9 months ago

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

May 13, 2024, 5:00 AM EDT - 10 months ago

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

May 10, 2024, 7:48 PM EDT - 10 months ago

Recursion Pharmaceuticals CEO Chris Gibson goes one-on-one with Jim Cramer

May 10, 2024, 7:47 PM EDT - 10 months ago

We've built an unbiased platform that lets data drive decisions, not us, says Recursion CEO

May 9, 2024, 10:53 PM EDT - 10 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 10 months ago

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

May 2, 2024, 8:00 AM EDT - 10 months ago

Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9

May 1, 2024, 8:01 AM EDT - 10 months ago

Recursion to Participate in Upcoming Investor Conferences

Apr 21, 2024, 9:02 PM EDT - 10 months ago

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

SANA VKTX

Apr 16, 2024, 8:00 AM EDT - 11 months ago

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Mar 26, 2024, 8:00 AM EDT - 11 months ago

Recursion Publishes Annual Environmental, Social and Governance Report

Mar 16, 2024, 6:34 AM EDT - 1 year ago

Not just Soundhound, these AI stocks are also riding Nvidia wave

NVDA SOUN ARM NNOX